Package 50242-061-01

{"route": ["INTRAVENOUS"], "spl_id": "8debebf6-af94-4ba7-8d67-c801f4ea27eb", "openfda": {"nui": ["N0000193543", "N0000178291", "N0000193542"], "unii": ["2S9ZZM9Q9V"], "rxcui": ["1657066", "1657068", "1657073", "1657074"], "spl_set_id": ["939b5d1f-9fb2-4499-80ef-0607aa6b114e"], "pharm_class_epc": ["Vascular Endothelial Growth Factor Inhibitor [EPC]"], "pharm_class_moa": ["Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]", "Vascular Endothelial Growth Factor Inhibitors [MoA]"], "manufacturer_name": ["Genentech, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-USE in 1 CARTON (50242-061-01)  / 16 mL in 1 VIAL, SINGLE-USE", "package_ndc": "50242-061-01", "marketing_start_date": "20040226"}], "brand_name": "Avastin", "product_id": "50242-061_8debebf6-af94-4ba7-8d67-c801f4ea27eb", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Vascular Endothelial Growth Factor Inhibitor [EPC]", "Vascular Endothelial Growth Factor Inhibitors [MoA]", "Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]"], "product_ndc": "50242-061", "generic_name": "bevacizumab", "labeler_name": "Genentech, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Avastin", "active_ingredients": [{"name": "BEVACIZUMAB", "strength": "400 mg/16mL"}], "application_number": "BLA125085", "marketing_category": "BLA", "marketing_start_date": "20040226", "listing_expiration_date": "20261231"}